Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. | Semantic Scholar
PD-(L)1 inhibition alone and in combination: recent insights into immunotherapy - memoinOncology
Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) for... | Download Scientific Diagram
First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study - Amrane - 2020 - Cancer Medicine - Wiley Online Library
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater | Journal of Clinical Oncology
KEYNOTE-024 and KEYNOTE-042 - First-line Monotherapy for Advanced NSCLC Clinical Trial Results
Retracted: First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset - Satouchi - 2020 - Cancer Science - Wiley Online Library
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer | NEJM
Efficacy - MSD Connect
First-line immune checkpoint inhibition in metastatic NSCLC - Medical Conferences
KEYNOTE 24: Pembrolizumab vs. Chemotherapy
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials - Borghaei - 2020 - Cancer -
Immunotherapy: novel biomarkers on the horizon & news from pivotal trials - memoinOncology
Tatiana Prowell, MD on Twitter: "#ESMO20 KEYNOTE-024: Pembro vs doublet chemo in 1L PDL1+ (50+%) #lungcancer OS 5y follow-up: 32% alive on P vs 16% on chemo. Almost 2/3 of pts crossed
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 - JTO Clinical and Research Reports
European Society of Medical Oncology 2016 Congress - ppt download
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands | Scientific Reports
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. | Semantic Scholar
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 - Journal of Thoracic Oncology
Immune checkpoint inhibition: the picture is slowly completing itself - memoinOncology
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
Overall survival in the Japanese subgroup in KEYNOTE-181. A All... | Download Scientific Diagram
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 - ScienceDirect
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression | SpringerLink
ESMO20 highlights | Get an overview of the five year data from the KEYNOTE- 024 - Pembrolizumab double the 5-year OS rate for patients with metastatic, PD-L1-positive lung... | By BestPractice Nordic Norge
KEYNOTE 24: Pembrolizumab vs. Chemotherapy
